Sort
48,018 grants matching “immunotherapy”
Targeting the cancer glycocalyx
$503,708Carolyn R Bertozzi · Stanford University · R01 · FY2025 · CA
Tousled like kinase signaling in cancer
$503,629Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
GENETICALLY ENGINEERED T CELLS FOR DIPG
$503,626Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2022 · NS
GENETICALLY ENGINEERED T CELLS FOR DIPG
$503,626Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2023 · NS
The Role of the Adenosine Receptor in Th Cell Development and Function
$503,617Peter B Ernst · University Of California, San Diego · R01 · FY2022 · AI
The Role of the Adenosine Receptor in Th Cell Development and Function
$503,617Peter B Ernst · University Of California, San Diego · R01 · FY2020 · AI
The Role of the Adenosine Receptor in Th Cell Development and Function
$503,617Peter B Ernst · University Of California, San Diego · R01 · FY2019 · AI
The Role of the Adenosine Receptor in Th Cell Development and Function
$503,617Peter B Ernst · University Of California, San Diego · R01 · FY2021 · AI
Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia
$503,583Nicholas Chiorazzi · Feinstein Institute For Medical Research · R01 · FY2022 · CA
Project 4:High Capacity Polymeric Micelle Therapeutics for Lung Cancer
$503,540Alexander V Kabanov · Univ Of North Carolina Chapel Hill · U54 · FY2016 · CA
Phosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T Cells
$503,539Erika L Pearce · Johns Hopkins University · R01 · FY2022 · AI
Phosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T Cells
$503,539Erika L Pearce · Johns Hopkins University · R01 · FY2024 · AI
Proj. 1 Targeting Tumor-Specific Neoepitopes for Glioblastoma Immunotherapy
$503,520David Reardon · Brigham And Women'S Hospital · P01 · FY2024 · CA
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival
$503,520Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2014 · CA
Innate Immunity to Spiral Ganglion Neuron Degeneration
$503,485Tejbeer Kaur · Rutgers Biomedical And Health Sciences · R01 · FY2024 · DC
Understanding the induction of T cell dysfunction in the context of lung cancer
$503,480Stefani Spranger · Massachusetts Institute Of Technology · R37 · FY2024 · CA
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ
$503,363Robert C Rostomily · Methodist Hospital Research Institute · R01 · FY2023 · NS
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$503,337Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$503,337Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
In Utero Stem Cell Transplantation
$503,330Esmail D Zanjani · University Of Nevada Reno · R01 · FY2009 · HL
A HER-2/neu pulsed DC1 vaccine for patients with DCIS
$503,290Brian Joseph Czerniecki · University Of Pennsylvania · R01 · FY2011 · CA
Characterizing head and neck tumor neoantigensand T cells: looking beyond the usual suspects
$503,244John B Sunwoo · Stanford University · R01 · FY2019 · DE
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
$503,234Yong Wan · Emory University · R01 · FY2025 · CA
Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models
$503,194James M Olson · Seattle Children'S Hospital · R21 · FY2024 · CA
Mechanisms of Hepatitis C Virus Evolution
$503,137Stuart C Ray · Johns Hopkins University · R01 · FY2008 · DA